PGPrakash Chandra Gupta

Prakash Chandra Gupta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Prakash Chandra Gupta has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Life Cycle Assessment of Nanomaterials in Environmental Applications

    by Riya Sachan, Nisha Sharma, Prakash Chandra Gupta

  • Open Access

    Repurposing Drugs and Phytochemicals in Leishmaniasis Therapy: Emerging Strategies and Translational Potential

    by Priyanka Mishra, Nisha Sharma, Debmalya Roy, Prakash Chandra Gupta, Bhupendra G. Prajapati, Shrikant Vijayrao Joshi, Sonia Pandey

    Leishmaniasis, a vector‐borne disease caused by protozoan parasites of the genus Leishmania , is a significant global challenge, particularly in resource‐constrained areas. The treatment of leishmaniasis has remained stagnant for over 70 years since the discovery of pentavalent antimonials (SbV), with no novel antileishmanial drugs developed during this period, reflecting limited engagement from academia and the pharmaceutical industry. Numerous FDA‐approved and investigational pharmaceuticals, initially designed for cancer, fungal, viral, or inflammatory disorders, have encouraging antileishmanial efficacy. The recent clinical landscape highlights that all three new treatments—amphotericin‐B, paromomycin, and miltefosine—are repurposed drugs rather than novel compounds. The current antileishmanial drug pipeline is notably sparse, with LXE 408 as the only candidate progressing to phase II clinical trials. Only two emerging candidates (DNDI‐6174 and ChAd63‐KH vaccine) are ready for preclinical/clinical studies. This scenario underscores an urgent need for drug repurposing strategies to accelerate the availability of effective therapies. Concurrently, phytotherapy offers promising adjunctive or alternative options due to the bioactive potential of plant‐derived compounds, as demonstrated by varying antileishmanial activities against different Leishmania species. Integrating drug repurposing with phytotherapeutic approaches could address the gaps in treatment options and combat species‐specific drug susceptibilities, thereby enhancing therapeutic outcomes in leishmaniasis management.


  • Diagnosis and Management of Thyroid Dysfunction in Postpartum Women: A Narrative Review

    by Neha, Zeeshan Ansari, Preeti Kamal, Priyanka Sonker, Nisha Sharma, Anuradha Kalani, Prakash Chandra Gupta

    Introduction: Postpartum thyroid dysfunction (PPTD), particularly postpartum thyroiditis, is a prevalent yet under recognized endocrine disorder affecting women within the first year after childbirth. It may present as transient hyperthyroidism, hypothyroidism, or both, and up to 20–30% of cases progress to permanent hypothyroidism. Immune system modulation during and after pregnancy, especially in women with thyroid peroxidase (TPO) antibodies, plays a central role in its pathogenesis. Methods: This article presents a narrative overview of recent literature published over the past 10 years. Relevant sources were identified through searches in scientific databases such as PubMed, Scopus, Web of Science, and Google Scholar. Results: Emerging tools (liquid biopsy, molecular imaging, next-generation sequencing) and AI algorithms enhance early detection. Targeted screening is recommended for high-risk women, particularly those with autoimmune thyroid disease or TPO antibodies. Therapeutic strategies include selenium/ iodine supplementation, hormone replacement, and immunomodulatory agents. Telemedicine shows potential for individualized care. Discussion: Our findings indicate that PPTD remains underdiagnosed (5-10% prevalence) despite clear autoimmune involvement (60% TPOAb-positive). Symptom overlap with normal postpartum recovery and inconsistent screening protocols contribute to diagnostic delays. While novel tools show diagnostic potential, their validation remains incomplete. The 20-30% progression to permanent hypothyroidism warrants targeted screening and personalized management. Future studies should optimize screening cost-effectiveness and evaluate long-term child development outcomes. Conclusion: Despite advancements, PPTD diagnosis remains challenging due to non-specific symptoms. A multidisciplinary approach integrating emerging technologies and public health initiatives is essential. Future research should focus on predictive models and long-term prevention strategies.

  • Flowers in Mental Health

    by Ashish Verma, Zeeshan Ansari, Muinur Rahman, Nisha Sharma, Prakash Chandra Gupta

  • Pharmacology, Phytochemistry, and Medicinal Use of Echinacea (Echinacea Purpurea)

    by Shivam Verma, Zeeshan Ansari, Abhishek Kumar Singh, Jay Kumar, Nisha Sharma, Prakash Chandra Gupta

  • Use of Copper-Based Nanomaterials in Postharvest Management

    by Prakash Chandra Gupta, Monika Dwivedi, Vishal Chand, Nisha Sharma, Priyanka Mishra, Shivam Verma

  • A Promising Approach to Target Cancer for Anticancer Drug Delivery via Engineered Cubosomal Nanocarriers

    by Apoorv Mishra, Nisha Sharma, Priyanka Mishra, Prashant Pandey, Prakash Chandra Gupta, Shilpa Deshpande Kaistha

    Carcinoma is a worldwide concern of well-being that leads health concern leading to mor-tality and disability. Although current treatment procedures offer some efficacy, they are not devoid of constraints and potential adverse reactions. Over the past few years, tremendous progress has emerged in newer strategies like immunotherapy and novel drug delivery systems, such as designing formula-tions utilising utilizing non-lamellar liquid-crystalline nanoparticles, known as lyotropic systems. Among them, cubosomes are one of the distinct categories of nanocarriers, formed by utilising utilizing precise proportions of amphiphilic lipids. Cubosomes are known for their ability to be compatible with living organisms and their flexibility in transporting drugs, allowing for the administration of pharma-ceuticals through many pathways. Several preclinical investigations have been reported to explore the future of cubosomes in cancer therapy and theranostic applications. The findings suggest that nano-technology and cancer therapies like immunotherapy have significant potential for tailored and effi-cient treatment approaches. Cubosomes can offer a promising contribution to the discipline of cancer research and the goal of enhancing therapeutic innovations. However, extensive research is required to confirm the safety, drug release mechanism, and stability of these nanocarriers. It covers a brief overview of cancer therapy including immunotherapy, advantages of targeted drug delivery, general aspects on of cubosomes, types of cubosomes, structural components, and preparation methods, fol-lowed by the mechanism of release, and discoveries on cubosomes as drug delivery for various cancers covering breast, colorectal, lung, liver, cervical, skin, etc. along with the future perspectives of other novel therapies like immunology in cancer.


  • Top Cited Papers

    Exploring inflammatory and fibrotic mechanisms driving diabetic nephropathy progression

    by Zeeshan Ansari, Ayush Chaurasia, Neha, Nisha Sharma, Rakesh Kumar Bachheti, Prakash Chandra Gupta


  • Top Cited Papers

    Comprehensive insights into leishmaniasis: From etiopathogenesis to a novel therapeutic approach

    by Zeeshan Ansari, Ayush Chaurasia, Neha, Anuradha Kalani, Rakesh Kumar Bachheti, Prakash Chandra Gupta


  • Properties and Synthesis of Chitin-Based Nanoparticles

    by Nisha Sharma, Kalpana Kushwaha, Swarnakshi Upadhyay, Priyanka Mishra, Sweta Rai, Jay Kumar, Prakash Chandra Gupta